Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.

Michael A Nauck Jean-Louis Frossard Jamie S BarkinGreg AnglinIngrid E HensleyKristine D Harper Zvonko Milicevic

Published in: Diabetes care (2017)

The exposure-adjusted incidence rate of acute pancreatitis in dulaglutide-treated patients was similar to the rates with placebo, with few reported cases during the entire program.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
risk factors
randomized controlled trial
clinical trial
study protocol
open label